Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ponesimod

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 277,540Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Juvisé Acquires Multiple Sclerosis Drug PONVORY and also Opens Its Capital
    Juvisé Acquires Multiple Sclerosis Drug PONVORY and also Opens Its Capital

    26 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240325471791/en

    BUSINESSWIRE
    26 Mar 2024
    Share Share
    Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY
    Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY

    25 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-a-us-patent-allowance-for-ponvory-ponesimod-in-the-us-302045334.html

    PR NEWSWIRE
    25 Jan 2024
    Share Share
    J&J unloads certain Ponvory rights to Vanda for $100M
    J&J unloads certain Ponvory rights to Vanda for $100M

    08 Dec 2023

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/vanda-scoops-johnson-johnsons-multiple-sclerosis-med-ponvory-100m

    FIERCE PHARMA
    08 Dec 2023
    Share Share
    Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY
    Vanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY

    07 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-acquires-us-and-canadian-rights-to-ponvory-ponesimod-a-selective-s1p1r-modulator-approved-for-patients-with-relapsing-multiple-sclerosis-302008402.html

    PR NEWSWIRE
    07 Dec 2023
    Share Share
    NICE recommends PONVORY for treatment of relapsing forms of multiple sclerosis
    NICE recommends PONVORY for treatment of relapsing forms of multiple sclerosis

    04 Jan 2022

    // PHARMAFILE

    http://www.pharmafile.com/news/602159/nice-recommends-ponvory-treatment-relapsing-forms-multiple-sclerosis

    PHARMAFILE
    04 Jan 2022
    Share Share
    SMC accepts oral therapy for relapsing multiple sclerosis
    SMC accepts oral therapy for relapsing multiple sclerosis

    10 Nov 2021

    // PHARMATIMES

    https://www.pharmatimes.com/news/smc_accepts_oral_therapy_for_relapsing_multiple_sclerosis_1383254

    PHARMATIMES
    10 Nov 2021
    Share Share